Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Ann Willman Silk, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Shalhout SZ, Emerick KS, Kaufman HL, Silk AW, Thakuria M, Miller DM. A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma. J Immunother. 2022 Sep 01; 45(7):299-302. PMID: 35877101.
    Citations:    Fields:    
  2. Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors. Eur J Med Res. 2022 Jul 02; 27(1):107. PMID: 35780243; PMCID: PMC9250196.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  3. Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson EJ, Madden K, Miller DM, Nghiem P, Pavlick AC, Puzanov I, Rabinowits G, Ruiz ES, Sondak VK, Tavss EA, Tetzlaff MT, Brownell I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. J Immunother Cancer. 2022 07; 10(7). PMID: 35902131; PMCID: PMC9341183.
    Citations:    Fields:    
  4. Liu KX, Milligan MG, Schoenfeld JD, Tishler RB, Ng AK, Devlin PM, Fite E, Rabinowits G, Hanna GJ, Silk AW, Yoon CH, Thakuria M, Margalit DN. Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma. Radiother Oncol. 2022 08; 173:32-40. PMID: 35595174.
    Citations:    Fields:    
  5. Mehnert JM, Mitchell TC, Huang AC, Aleman TS, Kim BJ, Schuchter LM, Linette GP, Karakousis GC, Mitnick S, Giles L, Carberry M, Frey N, Kossenkov A, Groisberg R, Hernandez-Aya LF, Ansstas G, Silk AW, Chandra S, Sosman JA, Gimotty PA, Mick R, Amaravadi RK. BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma. Clin Cancer Res. 2022 03 15; 28(6):1098-1106. PMID: 35022320; PMCID: PMC8923957.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  6. Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens AB, Leiser A, Mayer T, Chan N, Spencer K, Girda E, Malhotra J, Chan T, Subbiah V, Groisberg R. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022 02; 7(1):100336. PMID: 34953399; PMCID: PMC8717431.
    Citations: 6     Translation:Humans
  7. In GK, Thomas JS, Silk AW. Cutaneous Malignancies of the Head and Neck. Hematol Oncol Clin North Am. 2021 10; 35(5):991-1008. PMID: 34281755.
    Citations:    Fields:    Translation:Humans
  8. Nguyen HM, Bommareddy PK, Silk AW, Saha D. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. Semin Cancer Biol. 2021 May 24. PMID: 34033895.
    Citations: 4     Fields:    
  9. Larocca CA, LeBoeuf NR, Silk AW, Kaufman HL. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions. Am J Clin Dermatol. 2020 Dec; 21(6):821-832. PMID: 32767272.
    Citations: 6     Fields:    Translation:HumansCells
  10. Kacew AJ, Dharaneeswaran H, Starrett GJ, Thakuria M, LeBoeuf NR, Silk AW, DeCaprio JA, Hanna GJ. Predictors of immunotherapy benefit in Merkel cell carcinoma. Oncotarget. 2020 Nov 24; 11(47):4401-4410. PMID: 33315984.
    Citations: 3     Fields:    
  11. Chipidza FE, Thakuria M, Schoenfeld JD, Silk AW, Catalano PJ, Yoon CH, Hanna GJ, DeCaprio JA, Tishler RB, Margalit DN. Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy. J Am Acad Dermatol. 2021 Mar; 84(3):875-877. PMID: 33171164.
    Citations:    Fields:    Translation:Humans
  12. Wang SJ, Khullar K, Kim S, Yegya-Raman N, Malhotra J, Groisberg R, Crayton SH, Silk AW, Nosher JL, Gentile MA, Mehnert JM, Jabbour SK. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. J Immunother Cancer. 2020 10; 8(2). PMID: 33020239.
    Citations: 13     Fields:    Translation:Humans
  13. Hanna GJ, Ruiz ES, LeBoeuf NR, Thakuria M, Schmults CD, Decaprio JA, Silk AW. Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br J Cancer. 2020 11; 123(10):1535-1542. PMID: 32868898; PMCID: PMC7653959.
    Citations: 7     Fields:    Translation:Humans
  14. Danesh MJ, Mulvaney PM, Murakami N, Riella LV, Silk AW, Hanna GJ, Schmults CD. Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy. Cancer Immunol Immunother. 2020 09; 69(9):1937-1941. PMID: 32588077.
    Citations: 4     Fields:    Translation:Humans
  15. Wang SJ, Jhawar SR, Rivera-Nunez Z, Silk AW, Byun J, Miller E, Blakaj D, Parikh RR, Weiner J, Goyal S. The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients. Cureus. 2020 Jun 22; 12(6):e8767. PMID: 32714704; PMCID: PMC7377654.
    Citations: 3     
  16. Hall ET, Fernandez-Lopez E, Silk AW, Dummer R, Bhatia S. Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-10. PMID: 32207669.
    Citations: 9     Fields:    Translation:Humans
  17. Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Front Oncol. 2019; 9:1483. PMID: 31998643; PMCID: PMC6965158.
    Citations: 4     
  18. Seiger K, Mostaghimi A, Silk AW, Schmults CD, Ruiz ES. Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017. JAMA Oncol. 2020 01 01; 6(1):154-156. PMID: 31697307; PMCID: PMC6865225.
    Citations:    Fields:    Translation:Humans
  19. Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, Estupinian R, Aboelatta MM, Buddhadev S, Tarabichi S, Lee M, Li S, Medina DJ, Giurini EF, Gupta KH, Guevara-Aleman G, Rossi M, Nowicki C, Abed A, Goldufsky JW, Broucek JR, Redondo RE, Rotter D, Jhawar SR, Wang SJ, Kohlhapp FJ, Kaufman HL, Thomas PG, Gupta V, Kuzel TM, Reiser J, Paras J, Kane MP, Singer EA, Malhotra J, Denzin LK, Sant'Angelo DB, Rabson AB, Lee LY, Lasfar A, Langenfeld J, Schenkel JM, Fidler MJ, Ruiz ES, Marzo AL, Rudra JS, Silk AW, Zloza A. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc Natl Acad Sci U S A. 2020 01 14; 117(2):1119-1128. PMID: 31888983; PMCID: PMC6969546.
    Citations: 46     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  20. Seiger K, Schmults CD, Silk AW, Ruiz ES. Cost and utilization of immunotherapy and targeted therapy for melanoma: Cross-sectional analysis in the Medicare population, 2013 and 2015. J Am Acad Dermatol. 2020 03; 82(3):761-764. PMID: 31626884.
    Citations: 1     Fields:    Translation:Humans
  21. LoPiccolo J, Schollenberger MD, Dakhil S, Rosner S, Ali O, Sharfman WH, Silk AW, Bhatia S, Lipson EJ. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. J Immunother Cancer. 2019 07 08; 7(1):170. PMID: 31287031.
    Citations: 11     Fields:    Translation:Humans
  22. Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, Chesson CB, Sadimin ET, Li S, Medina DJ, Saunders T, Frankel M, Kareddula A, Damare S, Wesolowsky E, Gabel C, El-Deiry WS, Prabhu VV, Allen JE, Stogniew M, Oster W, Bertino JR, Libutti SK, Mehnert JM, Zloza A. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Immunother Cancer. 2019 05 22; 7(1):136. PMID: 31118108; PMCID: PMC6532211.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  23. Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019 02 18; 7(1):49. PMID: 30777131; PMCID: PMC6380045.
    Citations: 34     Fields:    Translation:Humans
  24. Silk AW, Margolin K. Cytokine Therapy. Hematol Oncol Clin North Am. 2019 04; 33(2):261-274. PMID: 30832999.
    Citations: 6     Fields:    Translation:Humans
  25. Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2019; 8(1):e1524695. PMID: 30546965.
    Citations: 18     Fields:    
  26. Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 11 15; 24(22):5552-5561. PMID: 30045932; PMCID: PMC6239933.
    Citations: 70     Fields:    Translation:HumansCellsCTClinical Trials
  27. Lasfar A, Zloza A, Silk AW, Lee LY, Cohen-Solal KA. Interferon Lambda: Toward a Dual Role in Cancer. J Interferon Cytokine Res. 2019 01; 39(1):22-29. PMID: 30020822.
    Citations: 10     Fields:    Translation:HumansCells
  28. Mehnert JM, Silk AW, Lee JH, Dudek L, Jeong BS, Li J, Schenkel JM, Sadimin E, Kane M, Lin H, Shih WJ, Zloza A, Chen S, Goydos JS. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma. Pigment Cell Melanoma Res. 2018 07; 31(4):534-540. PMID: 29453787.
    Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
  29. Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. J Natl Cancer Inst. 2018 03 01; 110(3):316-320. PMID: 29155997; PMCID: PMC6658862.
    Citations: 81     Fields:    Translation:HumansCells
  30. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017 11 21; 5(1):95. PMID: 29162153; PMCID: PMC5697162.
    Citations: 557     Fields:    Translation:Humans
  31. Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, Schenkel JM, Silk AW, Zloza A. Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies. Front Oncol. 2017; 7:202. PMID: 28955655; PMCID: PMC5600978.
    Citations: 43     
  32. Bommareddy PK, Silk AW, Kaufman HL. Intratumoral Approaches for the Treatment of Melanoma. Cancer J. 2017 Jan/Feb; 23(1):40-47. PMID: 28114253.
    Citations: 20     Fields:    Translation:HumansAnimals
  33. Jhawar SR, Silk AW, Goyal S. Pseudoprogression of a spinal metastasis after stereotactic ablative body radiation therapy and immune checkpoint therapy. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):109-112. PMID: 28274394.
    Citations: 1     Fields:    Translation:Humans
  34. Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016; 4:53. PMID: 27660707; PMCID: PMC5029010.
    Citations: 122     Fields:    
  35. Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for Immunotherapy: Current Developments and Challenges. Am Soc Clin Oncol Educ Book. 2016; 35:e493-503. PMID: 27249758.
    Citations: 47     Fields:    Translation:HumansCells
  36. Goyal S, Silk AW, Tian S, Mehnert J, Danish S, Ranjan S, Kaufman HL. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncol. 2015 Aug; 1(5):668-76. PMID: 26181286.
    Citations: 32     Fields:    Translation:Humans
  37. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013 Dec; 2(6):899-906. PMID: 24403263.
    Citations: 124     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Silk's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (135)
Co-Authors (28)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.